47 results on '"Enama, Mary E."'
Search Results
2. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial
3. Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial
4. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial
5. Supplemental Materials for Safety and Immunogenicity of Chimpanzee Adenovirus Vector Ebola Vaccine
6. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination
7. Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine
8. Prime-Boost Interval Matters: A Randomized Phase 1 Study to Identify the Minimum Interval Necessary to Observe the H5 DNA Influenza Vaccine Priming Effect
9. Therapeutic Vaccination Expands and Improves the Function of the HIV-Specific Memory T-Cell Repertoire
10. Chimpanzee Adenovirus Vector Ebola Vaccine
11. The Safety and Pharmacokinetics of Single-Agent and Combination Therapy with Megestrol Acetate and Dronabinol for the Treatment of HIV Wasting Syndrome
12. Randomization to standard and concise informed consent forms: Development of evidence-based consent practices
13. A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial
14. An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial
15. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
16. A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial
17. Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 DNA Candidate Vaccine
18. Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 Candidate Vaccine Delivered by a Replication-Defective Recombinant Adenovirus Vector
19. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial
20. Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
21. Safety and immunogenicity of a gag-pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects
22. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine
23. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax ® challenge in vaccinia-naïve and vaccinia-immune individuals
24. A West Nile virus dna vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial
25. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine
26. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector
27. Early Bactericidal Activity of Isoniazid in Pulmonary Tuberculosis: Optimization of Methodology
28. Chimpanzee Adenovirus Vector Ebola Vaccine - Preliminary Report
29. Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial.
30. DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial.
31. Corrigendum: Protection against malaria at 1 year and immune correlates following PfSPZ vaccination
32. Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost
33. Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012).
34. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection.
35. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax® challenge in vaccinia-naïve and vaccinia-immune individuals
36. DNA Priming for Seasonal Influenza Vaccine: A Phase 1b Double-Blind Randomized Clinical Trial.
37. Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults.
38. Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial.
39. Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011).
40. Therapeutic Vaccination Expands and Improves the Function of the HIV-Specific Memory T-Cell Repertoire.
41. DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial.
42. Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses.
43. Safety and Immunogenicityofa Gag-Pol Candidate HIV-1 DNA Vaccine Administered by a Needle-Free Device in HIV-1—Seronegative Subjects.
44. A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical Trial
45. Correction: Corrigendum: Protection against malaria at 1 year and immune correlates following PfSPZ vaccination
46. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial.
47. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax® challenge in vaccinia-naïve and vaccinia-immune individuals
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.